Actionnariat et activité des initiés pour Inovio Pharmaceuticals, Inc. (INO): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $1.15 |
| Capitalisation | $79M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $19.1M | $23.8M | $23.7M | $22.2M | $250.7M | $71.1M | $46.3M | $14.3M | $65.8M | $44.3M |
| Placements à Court Terme | $85.6M | $103.6M | $57.5M | $67.3M | $160.9M | $330.2M | $206.7M | $131.0M | $28.3M | $14.2M |
| Créances | $16.6M | $6.5M | $4.1M | $2.0M | $19.1M | $8.0M | $11.7M | $2.4M | $1.2M | $450 |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $124.6M | $138.4M | $87.8M | $94.2M | $471.2M | $448.4M | $315.2M | $153.1M | $97.8M | $61.1M |
| Immobilisations Corporelles | $9.0M | $18.3M | $15.9M | $26.6M | $24.1M | $29.0M | $18.0M | $14.5M | $11.8M | $9.1M |
| Goodwill | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | 0 | 0 | 0 |
| Actifs Incorporels | $7.6M | $6.0M | $4.8M | $3.7M | $3.1M | $2.6M | $2.1M | 0 | 0 | 0 |
| Actifs Totaux | $173.7M | $187.2M | $131.1M | $144.0M | $539.8M | $495.9M | $348.5M | $171.0M | $113.2M | $74.3M |
| Dettes Fournisseurs | $7.0M | $8.5M | $11.0M | $7.6M | $1.5M | $28.0M | $21.1M | $4.6M | $6.4M | $2.6M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $16.8M | 0 | 0 |
| Passifs Courants | $43.8M | $35.4M | $35.3M | $32.0M | $41.7M | $65.7M | $96.9M | $42.6M | $35.3M | $43.7M |
| Dette à Long Terme | 0 | 0 | 0 | $77.0M | $18.7M | $15.0M | $16.6M | 0 | 0 | 0 |
| Passifs Totaux | $50.3M | $44.8M | $44.1M | $138.5M | $78.6M | $96.3M | $126.2M | $53.6M | $44.7M | $50.2M |
| Réserves | -$434.8M | -$523.4M | -$620.4M | -$739.8M | -$906.2M | -$1.21B | -$1.49B | -$1.62B | -$1.73B | -$1.82B |
| Capitaux Propres | $123.3M | $142.4M | $86.9M | $3.4M | $461.1M | $399.7M | $222.4M | $117.3M | $68.5M | $24.1M |
| Dette Totale | 0 | 0 | 0 | $99.5M | $39.0M | $33.0M | $32.1M | $30.2M | $11.9M | $9.4M |
| Dette Nette | -$104.8M | -$127.4M | -$81.2M | $10.0M | -$372.6M | -$368.3M | -$220.9M | -$115.1M | -$82.2M | -$49.1M |
| Fonds de Roulement | $80.8M | $103.0M | $52.5M | $62.2M | $429.5M | $382.7M | $218.4M | $110.5M | $62.5M | $17.5M |
Santé financière
| Dette / Capitaux propres | 0.39 |
| Ratio de liquidité | 1.40 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -36.80 |
Rentabilité
| Rentabilité des capitaux propres | -352.53% |
| Rentabilité du capital investi | -259.45% |
| Rentabilité des actifs | -114.31% |
| Marge brute | 100.00% |
| Marge opérationnelle | -132871.32% |
| Marge nette | -130000.00% |
Entreprises liées: ABOS · ACTU · AGEN · ALEC · FATE · IRD · MCRB
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de INO: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions